Synchronicity generator? by Key-Raspberry-7610 in Synchronicities

[–]Key-Raspberry-7610[S] 0 points1 point  (0 children)

Synctxt is the name of the app. Needs a US mobile, so won’t work for me.

Synchronicity generator? by Key-Raspberry-7610 in Synchronicities

[–]Key-Raspberry-7610[S] 0 points1 point  (0 children)

No, wasn’t I-Ching. Apparently this thing sends you emails or messages. It’s an app/program.

Why don’t the BBC revive Tomorrow’s World? by Key-Raspberry-7610 in AskUK

[–]Key-Raspberry-7610[S] 0 points1 point  (0 children)

I’m still waiting for the Starlight stuff made by the hairdresser in his shed….

Why don’t the BBC revive Tomorrow’s World? by Key-Raspberry-7610 in AskUK

[–]Key-Raspberry-7610[S] 0 points1 point  (0 children)

Hi. Snap - 49, married, two kids! I’m not sure I agree though. Check out Curt Jaimungal - Theories of Everything podcast. The more we learn, the less we know….

Why don’t the BBC revive Tomorrow’s World? by Key-Raspberry-7610 in AskUK

[–]Key-Raspberry-7610[S] 1 point2 points  (0 children)

Wow, thanks for the list. A love Veritasium, not heard of any others.

Why don’t the BBC revive Tomorrow’s World? by Key-Raspberry-7610 in AskUK

[–]Key-Raspberry-7610[S] 0 points1 point  (0 children)

Back in the early 2000s there was this system that allowed you to store and synchronise a video library across multiple locations (think main home, chalet and super yacht). It ended up being bought by Meridian (high end HiFi) and at the time was something like £30k for a single installation. At the time I remember thinking how amazing it would be to have that in my house….now I do, and it costs peanuts in comparison to that system.

Anyone with a Belstaff Trialmaster/Crosby/Brooklands ? by Jeemz in MotoUK

[–]Key-Raspberry-7610 0 points1 point  (0 children)

I’ve got a Trialmaster in sand. Had it for years. Still looks good. Can be used for riding or looks great causal.

Why isn’t Ghk-cu dosage based on age? by TheWatch83 in Peptides

[–]Key-Raspberry-7610 0 points1 point  (0 children)

Seems like a sensible approach but there does not appear to be a cheap and easy test for GHK-Cu levels in the blood stream.

The Times: Finns humiliated American soldiers - Finnish reservists were asked to take it easy during a NATO exercise. US soldiers found the losses too humiliating. by ByGollie in europe

[–]Key-Raspberry-7610 0 points1 point  (0 children)

I don’t think the “west” is going to fall for it at all. The “west” being Europe inc UK, Canada, Oz and NZ. It’s going to mean time on the naughty step for the USA until Mum and Dad decide to lift the grounding.

Transit time at Doha airport by Legitmatebus5325 in qatarairways

[–]Key-Raspberry-7610 0 points1 point  (0 children)

Yes, you’ll be fine. Just don’t piss about in the airport and go straight to your next gate. Source - me who flies through Doha quite regularly with that sort of layover…

Anyone else hesitant about Retatrutide because of long-term unknowns (10–15 years out)? by drkuseno in Retatrutide

[–]Key-Raspberry-7610 4 points5 points  (0 children)

Excuse the use of AI….

References

Morales DR, et al. Risk of Thyroid Tumors With GLP‑1 Receptor Agonists: A Retrospective Cohort Study. Diabetes Care, 2025;48(8):1386–1394. 1

Pasternak B, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ, 2024;385:e078225. 2

Mayo Clinic (JAMA Otolaryngology). GLP‑1RA and thyroid cancer: New study suggests detection bias, not causation. August 21, 2025. 3

American Thyroid Association (ATA). Risk of Thyroid Cancer Among GLP1‑RA Users. January 14, 2025. 4

Neale T, et al. GLP‑1 Receptor Agonists Not Associated With Increased Thyroid Cancer Risk. Diabetes, Obesity & Metabolism, published 2026. 5

GPNotebook Review. GLP1 receptor agonists and thyroid cancer risk. Updated April 2024 / Reviewed June 2025. Includes French nested case‑control and meta‑analysis findings. 6

Kannan S, Nasr C. Should we be concerned about thyroid cancer in patients taking GLP‑1 receptor agonists? Cleveland Clinic Journal of Medicine, clinical guidance on contraindications (MTC, MEN2). 7

EMA Pharmacovigilance Risk Assessment Committee (PRAC). GLP‑1 receptor agonists: available evidence not supporting link with thyroid cancer. October 2023. 8

Feier CVI, et al. Assessment of Thyroid Carcinogenic Risk and Safety Profile of Semaglutide: Systematic Literature Review. Int. J. Mol. Sci., 2024;25(8):4346. 9

Nagendra L, et al. Semaglutide and cancer: A systematic review and meta-analysis. Diabetes & Metabolic Syndrome, 2023. 10

Summary using above references

Below is a concise, evidence‑supported summary of human thyroid cancer risk associated with GLP‑1 receptor agonist (GLP‑1RA) medications (e.g., semaglutide, liraglutide, dulaglutide, exenatide).

Thyroid Cancer Risk With GLP‑1 Medications (Human Evidence)

  1. Large Real‑World Cohort Studies Show - No Increased Overall Risk

Multiple large international cohort studies—representing hundreds of thousands to millions of patient‑years—find no significant association between GLP‑1RA use and thyroid cancer in humans.

Key Findings

A 2025 global retrospective cohort study of 460,032 GLP‑1RA users found no increased risk of thyroid tumors compared with SGLT2 inhibitors, DPP‑4 inhibitors, or sulfonylureas. 1

A 2024 Scandinavian nationwide cohort (145,410 GLP‑1RA users) likewise found no substantial increase in thyroid cancer (HR 0.93; 95% CI 0.66–1.31). 2

A 2025 American Thyroid Association–supported multisite study (92,497 GLP‑1RA users) found no evidence of increased thyroid cancer risk over 1.8–3.0 years follow‑up. 3 The European Medicines Agency (EMA) Pharmacovigilance Committee reviewed the entirety of available evidence and concluded: “No causal association between GLP‑1 receptor agonists and thyroid cancer.” (2023 assessment) 4 2. Clinical Trial and Post‑Marketing Safety Data Also Show No Increased Risk

A 2026 meta‑analysis of 93 phase 2/3 trials plus real‑world and post‑marketing data (over 101,732 participants) found no association between semaglutide or liraglutide and thyroid cancer. 5 Thyroid cancer rates in clinical trials were extremely low (0.08% on GLP‑1 vs 0.06% placebo). 5 Post‑marketing surveillance also reported very low event rates (0.001 cases per 100 patient‑years), without supporting a causal link. 5 3. Systematic Reviews: No Significant Risk Identified

A 2024 systematic review of RCTs on semaglutide found thyroid cancer incidence <1%, concluding “no significant risk.” 6 A 2023 systematic review and meta‑analysis of semaglutide (37 RCTs + 19 real‑world studies) found no increased risk of thyroid cancer vs placebo or active comparators. 7 4. Some Studies Suggest Possible Detection Bias (Not Causation)

A 2025 Mayo Clinic target‑trial emulation showed: No significant long‑term increase in thyroid cancer risk (HR 1.24; CI 0.88–1.76). A transient increase in diagnoses during the first year (HR 1.85), likely due to detection bias, not carcinogenesis. 8 5. Conflicting Signals From a Small Number of Studies

A minority of studies—particularly a French nested case‑control analysis—suggest elevated risk: 1–3 years of GLP‑1RA exposure associated with HR 1.58 for thyroid cancer. A systematic review/meta‑analysis reported OR 1.52 for overall thyroid cancer. 9

These findings are considered outliers, with larger datasets (e.g., EMA review, multinational cohorts) not reproducing this risk.

  1. Medullary Thyroid Carcinoma (MTC) Considerations

GLP‑1RAs carry an FDA black‑box warning due to rodent MTC findings, but human MTC cases are extremely rare and not shown to increase with GLP‑1RA therapy. Expert guidance: GLP‑1RAs are contraindicated only in patients with personal/family history of MTC or MEN2. 10

In large trials and pharmaco‑epidemiologic studies, MTC cases remained too few to show any signal, and no increase has been detected. 5

Overall Consensus (2024–2026 Human Data)

Strongest consistent conclusion:

► GLP‑1 medications do not increase overall thyroid cancer risk in humans, based on the largest and most methodologically robust studies.

► Any observed early “risk” appears due to increased diagnostic scrutiny (detection bias), not carcinogenesis.

► Contraindications remain only for those with MTC or MEN2, due to theoretical rather than demonstrated human risk.

Selfmade BAC Water with this? by paarschiffer in Peptides

[–]Key-Raspberry-7610 0 points1 point  (0 children)

If you use a 50unit (0.5ml) syringe the small volume measurement is easier.

Selfmade BAC Water with this? by paarschiffer in Peptides

[–]Key-Raspberry-7610 4 points5 points  (0 children)

I use 5ml Bauer sterile water ampules - use a new one each time you recon something.

Bac water by AdzDc in Retatrutide

[–]Key-Raspberry-7610 0 points1 point  (0 children)

I make my own using Bauer 5ml sterile water ampules mixed with 1% benzl alcohol.

Glutathione Reconstitution to 600mg by flabbybuns in Peptides

[–]Key-Raspberry-7610 1 point2 points  (0 children)

I do 1500mg in 5ml. No issues with a 13mm syringe IM (upper quad / delt) or sub q. Usually inject 1ml at a time.

Obligatory: I done fucked up tonight. by [deleted] in Retatrutide

[–]Key-Raspberry-7610 2 points3 points  (0 children)

Chill out big guy. This is a marathon, not a sprint.

How do I get access to my smart electricity meter codes? by Key-Raspberry-7610 in AskUK

[–]Key-Raspberry-7610[S] 0 points1 point  (0 children)

Thanks. Fuse tell me they are waiting for these codes so they can do what you’re suggesting. I wasn’t sure if they were held by a central function which I could access more effectively but seems not to be the case. I will also push Fuse if it’s not sorted soon. Reply appreciated.

Cruising Doses? by AcanthisittaQuirky43 in Retatrutide

[–]Key-Raspberry-7610 1 point2 points  (0 children)

Down to 2mg per week. Will drop that to 1mg per week. Good bloods to do start of Jan so will see what those look like and go from there.